Waldron Private Wealth LLC Sells 65 Shares of Thermo Fisher Scientific Inc. $TMO

Waldron Private Wealth LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 575 shares of the medical research company’s stock after selling 65 shares during the period. Waldron Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $233,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Linden Thomas Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 134.2% during the second quarter. Linden Thomas Advisory Services LLC now owns 12,638 shares of the medical research company’s stock worth $5,124,000 after purchasing an additional 7,241 shares during the period. Graybill Wealth Management LTD. raised its stake in shares of Thermo Fisher Scientific by 2.6% in the second quarter. Graybill Wealth Management LTD. now owns 13,326 shares of the medical research company’s stock valued at $5,403,000 after acquiring an additional 344 shares during the last quarter. Mcdaniel Terry & Co. raised its stake in shares of Thermo Fisher Scientific by 3.0% in the second quarter. Mcdaniel Terry & Co. now owns 31,597 shares of the medical research company’s stock valued at $12,811,000 after acquiring an additional 923 shares during the last quarter. City State Bank raised its stake in shares of Thermo Fisher Scientific by 2,133.3% in the second quarter. City State Bank now owns 335 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 320 shares during the last quarter. Finally, Keeler Thomas Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $786,000. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a report on Friday, July 11th. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Finally, Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $595.75.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock valued at $13,990,971 in the last three months. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $573.07 on Monday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The stock has a market cap of $216.40 billion, a PE ratio of 33.11, a PEG ratio of 3.35 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm’s 50 day moving average price is $504.04 and its two-hundred day moving average price is $453.56.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the business earned $5.28 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.